Insider Trades for Abeona Therapeutics Inc. show that the latest trade was made on 7 Nov 2016 where Ahn (Mark J), the Director completed a transaction type "Buy" in which 150000 shares were traded at a price of $2.31. BidaskClub lowered Abeona Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, July 27th.
Abeona Therapeutics (ABEO) said Monday that it intends to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. Maxim Group restated a "buy" rating and set a $17.00 target price (up previously from $14.00) on shares of Abeona Therapeutics in a research note on Tuesday, July 18th. They now have a United States dollars 35 price target on the stock.
(ABEO) was up +3.73% during the last trading session, with a day high of 17.30. The firm's market cap is $696.97 million. Abeona Therapeutics has a 12-month low of $4.05 and a 12-month high of $22.75. The company's 50 day moving average price is $15.53 and its 200 day moving average price is $8.77.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 15th. The analysts estimated EPS for the higher end at -0.09 and lower end at -0.22 while the year ago reported earnings per share was -0.19. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by ($0.07). Return on Equity (ROE) stands at -26.7% and Return on Investment (ROI) of 0 percent.
02/06/2017 - Abeona Therapeutics Inc. had its "buy" rating reiterated by analysts at Rodman & Renshaw.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald.
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., launched on June 22, 1989, is focused on developing and delivering gene therapy and plasma-based products for rare diseases.
Hartford Financial Management Inc. bolstered its holdings by buying 1,200 shares an increase of 6.7% from 06/30/2017 to 09/30/2017. State of Wisconsin Investment Board purchased a new position in Abeona Therapeutics in the 2nd quarter worth $122,000. Abeona Therapeutics earned a news impact score of 0.11 on Accern's scale. Abeona has offices in Cleveland, New York and Dallas.
Analysts are also projecting an Average Revenue Estimate for Abeona Therapeutics Inc.as $230000 in the Current Quarter. Institutional investors own 38.38% of the company's stock. The Business's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.